Application of individual technical calibration for evaluation of metabolic tumor volumes and variation in TLG (determined by mean SUV values and metabolic tumor volume) was admitted to be the best predictor of response to NAT when used at baseline and 12 weeks from NAT completion [49]. The gene discussed is BRD2; the disease is neoplasm.